본문 바로가기
KERD
논문KCI 등재

The evolving classifications and epidemiological challenges surrounding chronic migraine and medication overuse headache: a review

Emanuel Schembri|Michelle Barrow|Christopher McKenzie|Andrew Dawson
대한통증학회 (The Korean Pain Society)|2022.01|The Korean Journal of Pain|제35권 제1호|pp. 4-13|DOI 10.3344/kjp.2022.35.1.4

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

ClassificationSecondaryHeadacheAnalgesicsPrimaryBrain DiseasesHeadache DisordersMigraine Disorders.

초록

Changes in diagnostic criteria, for example, the various International Classification of Headache Disorders criteria, would lead to changes in the outcomes of epidemiological studies. International Classification of Headache Disorders-1 was based mainly on expert opinion, yet most of the diagnostic criteria were reliable and valid, but it did not include chronic migraine. In its second version, the classification introduced chronic migraine, but this diagnosis resembled more a high-frequency migraine rather than the actual migraine transformation process. It also introduced medication overuse headache, but it necessitated analgesic withdrawal and subsequent headache improvement to be diagnosed as such. Hence patients having medication overuse headache could only be diagnosed in retrospect, which was an awkward situation. Such restrictive criteria for chronic migraine and medication overuse headache omitted a high proportion of patients. International Classification of Headache Disorders-3 allows a diagnosis of medication overuse headache due to combination analgesics if taken for at least 10 days per month for more than three months. Hence the prevalence rate of medication overuse headache and chronic migraine can increase compared to the previous version of the headache classification. Different criteria have been used across studies to identify chronic migraine and medication overuse headache, and therefore the information acquired from previous studies using earlier criteria becomes uncertain. Hence much epidemiological research would need to be interpreted cautiously or repeated with the most updated criteria, since the subjects in studies that apply the latest criteria may be phenotypically different from those in older studies.

Abstract

Changes in diagnostic criteria, for example, the various International Classification of Headache Disorders criteria, would lead to changes in the outcomes of epidemiological studies. International Classification of Headache Disorders-1 was based mainly on expert opinion, yet most of the diagnostic criteria were reliable and valid, but it did not include chronic migraine. In its second version, the classification introduced chronic migraine, but this diagnosis resembled more a high-frequency migraine rather than the actual migraine transformation process. It also introduced medication overuse headache, but it necessitated analgesic withdrawal and subsequent headache improvement to be diagnosed as such. Hence patients having medication overuse headache could only be diagnosed in retrospect, which was an awkward situation. Such restrictive criteria for chronic migraine and medication overuse headache omitted a high proportion of patients. International Classification of Headache Disorders-3 allows a diagnosis of medication overuse headache due to combination analgesics if taken for at least 10 days per month for more than three months. Hence the prevalence rate of medication overuse headache and chronic migraine can increase compared to the previous version of the headache classification. Different criteria have been used across studies to identify chronic migraine and medication overuse headache, and therefore the information acquired from previous studies using earlier criteria becomes uncertain. Hence much epidemiological research would need to be interpreted cautiously or repeated with the most updated criteria, since the subjects in studies that apply the latest criteria may be phenotypically different from those in older studies.

참고문헌 (54)

  1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 392, pp.1789~1858 (2018)
  2. GBD 2016 Headache Collaborators, "Global, regional, and national burden of migraine and tension-type headache, 1990-2016 : a systematic analysis for the Global Burden of Disease Study 2016", Lancet Neurol, 17, pp.954~976 (2018)
  3. Steiner TJ, "Headache disorders are third cause of disability worldwide", J Headache Pain, 16, pp.58~ (2015)
  4. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016", Lancet, 390, pp.1211~1259 (2017)
  5. Silberstein SD, "Fremanezumab for the preventive treatment of chronic migraine", N Engl J Med, 377, pp.2113~2122 (2017)
  6. Giamberardino MA, "Anti-CGRP monoclonal antibodies in migraine : current perspectives", Intern Emerg Med, 11, pp.1045~1057 (2016)
  7. Linde M, "The cost of headache disorders in Europe : the Eurolight project", Eur J Neurol, 19, pp.703~711 (2012)
  8. Steiner TJ, "The impact of headache in Europe : principal results of the Eurolight project", J Headache Pain, 15, pp.31~ (2014)
  9. Steiner TJ, "Improving quality in population surveys of headache prevalence, burden and cost : key methodological considerations", J Headache Pain, 14, pp.87~ (2013)
  10. "Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society", Cephalalgia, 8(Suppl 7), pp.1~96 (1988)
  11. Headache Classification Subcommittee of the International Headache Society, "The International Classification of Headache Disorders: 2nd edition", Cephalalgia, 24(Suppl 1), pp.9~160 (2004)
  12. Headache Classification Committee of the International Headache Society(IHS), "The International Classification of Headache Disorders, 3rd edition(beta version)", Cephalalgia, 33, pp.629~808 (2013)
  13. Headache Classification Committee of the International Headache Society (IHS), "The International Classification of Headache Disorders, 3rd edition", Cephalalgia, 38, pp.1~211 (2018)
  14. Olesen J, "The international classification of headache disorders, 2nd edn(ICDH-II)", J Neurol Neurosurg Psychiatry, 75, pp.808~811 (2004)
  15. Silberstein SD, "Classification of daily and near-daily headaches : proposed revisions to the IHS criteria", Headache, 34, pp.1~7 (1994)
  16. Silberstein SD, "Classification of daily and near-daily headaches : field trial of revised IHS criteria", Neurology, 47, pp.871~875 (1996)
  17. Headache Classification Committee, "New appendix criteria open for a broader concept of chronic migraine", Cephalalgia, 26, pp.742~746 (2006)
  18. Manzoni GC, "ICHD-3 : what changes do we need regarding migraine", Curr Pain Headache Rep, 15, pp.170~176 (2011)
  19. Katsarava Z, "Chronic migraine : classification and comparisons", Cephalalgia, 31, pp.520~529 (2011)
  20. Olesen J, "International Classification of Headache Disorders, Second Edition(ICHD-2) : current status and future revisions", Cephalalgia, 26, pp.1409~1410 (2006)
  21. Bigal ME, "The International Classification of Headache Disorders revised criteria for chronic migraine—field testing in a headache specialty clinic", Cephalalgia, 27, pp.230~234 (2007)
  22. Bigal ME, "Field testing alternative criteria for chronic migraine", Cephalalgia, 26, pp.477~482 (2006)
  23. Straube A, "Prevalence of chronic migraine and medication overuse headache in Germany--the German DMKG headache study", Cephalalgia, 30, pp.207~213 (2010)
  24. Manzoni GC, "Chronic migraine classification : current knowledge and future perspectives", J Headache Pain, 12, pp.585~592 (2011)
  25. Jiang H, "Field testing of the ICHD-3β and expert opinion criteria for chronic migraine", J Headache Pain, 17, pp.85~ (2016)
  26. May A, "Chronic migraine : risk factors, mechanisms and treatment", Nat Rev Neurol, 12, pp.455~464 (2016)
  27. Russell MB, "Epidemiology and management of medicationoveruse headache in the general population", Neurol Sci, 40(Suppl 1), pp.23~26 (2019)
  28. Goadsby PJ, "Refractory migraine and chronic migraine : pathophysiological mechanisms", Headache, 48, pp.1399~1405 (2008)
  29. Torres-Ferrús M, "When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month", Cephalalgia, 37, pp.104~113 (2017)
  30. Manzoni GC, "Chronic headaches : a clinician’s experience of ICHD-3 beta", Neurol Sci, 36(Suppl 1), pp.51~55 (2015)
  31. Schwedt TJ, "Medication overuse headache : pathophysiological insights from structural and functional brain MRI research", Headache, 57, pp.1173~1178 (2017)
  32. Martelletti P, "The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine", J Headache Pain, 19, pp.2~ (2018)
  33. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015", Lancet, 388, pp.1545~1602 (2016)
  34. Vandenbussche N, "Medication-overuse headache : a widely recognized entity amidst ongoing debate", J Headache Pain, 19, pp.50~ (2018)
  35. Aurora SK, "OnabotulinumtoxinA for treatment of chronic migraine : results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial", Cephalalgia, 30, pp.793~803 (2010)
  36. Diener HC, "OnabotulinumtoxinA for treatment of chronic migraine : results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial", Cephalalgia, 30, pp.804~814 (2010)
  37. Dodick DW, "OnabotulinumtoxinA for treatment of chronic migraine : pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program", Headache, 50, pp.921~936 (2010)
  38. "Botulinum toxin type A for the prevention of headaches in adults with chronic migraine" (2012)[URL]
  39. Westergaard ML, "Definitions of medication-overuse headache in populationbased studies and their implications on prevalence estimates : a systematic review", Cephalalgia, 34, pp.409~425 (2014)
  40. Stewart WF, "Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors", JAMA, 267, pp.64~69 (1992)
  41. Lipton RB, "Prevalence and burden of migraine in the United States : data from the American Migraine Study II", Headache, 41, pp.646~657 (2001)
  42. Winter AC, "Associations of socioeconomic status with migraine and non-migraine headache", Cephalalgia, 32, pp.159~170 (2012)
  43. Castillo J, "Kaplan Award 1998. Epidemiology of chronic daily headache in the general population", Headache, 39, pp.190~196 (1999)
  44. Bigal ME, "Acute migraine medications and evolution from episodic to chronic migraine : a longitudinal population-based study", Headache, 48, pp.1157~1168 (2008)
  45. Buse DC, "Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study", Headache, 52, pp.1456~1470 (2012)
  46. Steiner TJ, "Diagnosis, prevalence estimation and burden measurement in population surveys of headache : presenting the HARDSHIP questionnaire", J Headache Pain, 15, pp.3~ (2014)
  47. Streel S, "One-year prevalence of migraine using a validated extended French version of the ID Migraine™: a Belgian population-based study", Rev Neurol (Paris), 171, pp.707~714 (2015)
  48. Streel S, "Validation of an extended French version of ID Migraine™ as a migraine-screening tool", Cephalalgia, 35, pp.437~442 (2015)
  49. Lipton RB, "A self-administered screener for migraine in primary care : the ID Migraine validation study", Neurology, 61, pp.375~382 (2003)
  50. da Silva A Jr, "Chronic headache and comorbidities : a two-phase, population-based, cross-sectional study", Headache, 50, pp.1306~1312 (2010)
  51. Hagen K, "Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trøndelag Health Studies", Pain, 153, pp.56~61 (2012)
  52. Global Burden of Disease Study 2013 Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013 : a systematic analysis for the Global Burden of Disease Study 2013", Lancet, 386, pp.743~800 (2015)
  53. Serrano D, "Fluctuations in episodic and chronic migraine status over the course of 1 year : implications for diagnosis, treatment and clinical trial design", J Headache Pain, 18, pp.101~ (2017)
  54. Steiner TJ, "Societal impact of headache: burden, costs and response", pp.83~104 (2019), Springer

관련 논문AI추천

Differences in Clinical Features and Disability according to the Frequency of Medication Use in Patients with Chronic Migraine박정욱, 서경임, 신혜은대한신경과학회 · Journal of Clinical Neurology2012 · 제8권 제3호Chronic Daily Headache and Medication Overuse Headache in First-Visit Headache Patients in Korea: A Multicenter Clinic-Based Study김병건, 김병수, 김수경, 김재문, 문희수, 박광열, 박정욱, 손종희, 송태진, 조수진, 차명진대한신경과학회 · Journal of Clinical Neurology2016 · 제12권 제3호약물과용두통: 진단기준, 역학, 치료박홍균, 조수진대한신경과학회 · 대한신경과학회지2023 · 제41권 제1호Chronic Daily Headache in Korea: Prevalence, Clinical Characteristics, Medical Consultation and Management김재문, 문희수, 박정욱, 이광수, 주민경대한신경과학회 · Journal of Clinical Neurology2014 · 제10권 제3호Differences in Characteristics and Comorbidity of Cluster Headache According to the Presence of Migraine김대영, 김병건, 김병수, 김수경, 김재문, 문희수, 박광열, 박정욱, 손종희, 송태진, 안진영, 오경미, 이미지, 정재면, 정진상, 정필욱, 조수진, 주민경, 최윤주대한신경과학회 · Journal of Clinical Neurology2019 · 제15권 제3호Polymorphism of the Glutamate Transporter Protein EAAT2 and Migraine Transformation into Chronic Daily Headache박정욱, 신혜은, 이광수, 한수정대한신경과학회 · Journal of Clinical Neurology2011 · 제7권 제3호

이 간행물의 다른 논문 (13건)

Timing of musculoskeletal steroid injections in pain practice during Coronavirus disease 2019 (COVID-19) vaccine administrationKyung-Hoon Kimpp. 1-3Steroid injections in pain management: influence on coronavirus disease 2019 vaccinesEun Joo Choi, Sung Man Hong, Yeon Wook Parkpp. 14-21The role of basolateral amygdala orexin 1 receptors on the modulation of pain and psychosocial deficits in nitroglycerin-induced migraine model in adult male ratsMehdi Abbasnejad, Saeed Esmaeili-Mahani, Ali Mohammad Pourrahimi, Razieh Kooshki, Khadijeh Askari-Zahabi, Maryam Raoof, Mahnaz Zamyadpp. 22-32Anti-nociceptive and anti-inflammatory activities of the essential oil isolated from Cupressus arizonica Greene fruitsHaroon Khan, Sajad Fakhri, Safoora Jafarian, Mohammad Bagher Majnooni, Mohammad Hosein Farzaei, Ehsan Mohammadi-Nooripp. 33-42The efficacy of GABAergic precursor cells transplantation in alleviating neuropathic pain in animal models: a systematic review and meta-analysisMostafa Hosseini, Mohammed I. M. Gubari, Arian Madani Neishaboori, Seyedeh Niloufar Rafiei Alavi, Solmaz Nasseri Maleki, Shaghayegh Askarian-Amiri, Amirmohammad Toloui, Arash Sarveazad, Mahmoud Yousefifardpp. 43-58
원문 보기